Personalize statin therapy following acute ischemic stroke
摘要
Statins are a cornerstone of secondary prevention following acute ischemic stroke (AIS). Widely used for their lipid-lowering effects, emerging evidence suggests the pleiotropic properties of statins provide a benefit in AIS management, including for patients with low baseline lipid levels. Established guidelines for statin therapy following AIS are inconsistent. Treatment optimization requires a personalised approach which considers stroke subtype and patient characteristics. Emerging strategies in statin care following AIS include novel drug-delivery systems improving bioavailability to the brain and combination therapies for patients with comorbid conditions or resistance to statin therapy.